HTA Quarterly | Summer 2020
By Xcenda
In this issue, our editors examine digital health technology (DHT) from a global perspective, the value drivers for emerging gene therapies for hemophilia, and the impact of the European Union’s new medical devices guidance on DHTs.
HTA QUARTERLY | SUMMER 2020
The Era of mHealth: A Global Perspective
Technology has the potential to make healthcare delivery more effective, efficient, and patient-centric through improved access to an abundance of data. As digital health technology (DHT) innovations become increasing inseparable from healthcare, a paradigm shift is imminent.
HTA QUARTERLY | SUMMER 2020
Emerging Gene Therapies for Hemophilia in the United States—Value Drivers in a Crystal Ball
Multiple gene therapies in development promise a potential cure for hemophilia by reversing the underlying genetic defect and removing the need for lifelong intravenous infusions of blood clotting factors. Given the high level of expectations, manufacturers need to carefully tailor the generation of appropriate evidence to demonstrate the value of their products to key stakeholders in the early adopting United States (US) market.
HTA QUARTERLY | SUMMER 2020
Regulatory and Market Access Impact in Europe of the Recent Medical Software Makers Guidance
As the role of technology in healthcare becomes increasingly important, and demand for new/innovative digital health technologies (DHTs) grows, understanding how the European Union’s new guidance on medical devices may affect the time to market and uptake of DHTs is essential.
white paper
The Potential Impact of Pharmaceutical and Non-Pharmaceutical Interventions to Mitigate the COVID-19 Crisis in the United States: A Model-Based Analysis
As policy makers assess and respond to the COVID-19 pandemic, how will the current and proposed future interventions and strategies possibly affect outcomes in the US? That’s a question Xcenda set out to investigate in its latest white paper. Using an infectious disease model, we analyze the potential impact of both non-pharmaceutical and pharmaceutical interventions in mitigating the COVID-19 health crisis.
Heard on the Street
“States are considering when and how to ease social distancing. But easing social distancing policies involves a tactically and strategically complex cost-benefit balancing act due to the potential exponential growth of COVID-19. Testing will be crucial for disease surveillance as social distancing policies are eased and large-scale testing followed by contact tracing and isolation can help reduce disease transmission as social distancing is eased. Read Xcenda’s white paper based on a SEIR infectious disease model of the COVID-19 crisis to learn more about these scenarios and others.”
- The Potential Impact of Pharmaceutical and Non-Pharmaceutical Interventions to Mitigate the COVID-19 Crisis in the United States: A Model-Based Analysis
HTA by the Numbers
141,000 COVID-19 Deaths
Xcenda’s COVID-19 susceptible-exposed-infected-recovered (SEIR) model base-case estimates (R0 = 3.2) 21.4 million infections, 141,000 deaths, and nearly $20 billion in total health costs in the US in 2020 as a result of the pandemic. Analyses were conducted to examine the potential impact of the level of disease transmission by varying R0, while assuming that social distancing reduces contact by 75% through the remainder of the year. The estimated number of total infections ranged from 14.1 million (R0 = 2.2) to 57.4 million (R0 = 4.2), while the number of deaths ranged from 93,000 (R0 = 2.2) to 376,000 (R0 = 4.2).
Topics:
Market access
COVID-19
